8-K: CytoSorbents Announces Shareholder Rights Offering to Bolster Liquidity

CytoSorbents Corporation has announced a rights offering to existing shareholders and certain warrantholders, aiming to raise capital and unlock restricted cash.

Summary

• CytoSorbents Corporation is initiating a rights offering where existing shareholders and certain warrantholders will receive one non-transferable subscription right for each share of common stock held.
• The record date for eligibility is December 16, 2024, with investors needing to hold or buy stock by the close of trading on December 13, 2024.
• Each subscription right allows the purchase of one unit at $1.00, consisting of one share of common stock, one Series A right warrant, and one Series B right warrant.
• The Series A right warrant is exercisable 45 days after the initial closing at 90% of the 5-day volume weighted average price, with a floor of $1.00 and a ceiling of $2.00.
• The Series B right warrant is exercisable 90 days after the initial closing at 90% of the 5-day volume weighted average price, with a floor of $2.00 and a ceiling of $4.00.
• The company aims to raise capital for general corporate purposes and to unlock $3.0 to $5.0 million in restricted cash on a dollar-for-dollar basis.
• The maximum number of units offered is 6.25 million, with an additional 6.25 million common shares reserved for warrant exercises, totaling 12.5 million shares.
• The subscription rights expire on January 10, 2025, and any unexercised rights or warrants after the maximum share issuance will expire worthless.
• Shareholders who fully exercise their basic subscription rights will also have an oversubscription privilege to purchase additional units not subscribed for by others, subject to pro-rata allocation.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While the rights offering is a necessary step for the company's financial health, it also introduces potential dilution and risks for shareholders. The potential for increased liquidity and product launches is positive, but the uncertainty of regulatory approvals and market conditions tempers the overall sentiment.

Positives

• The rights offering provides existing shareholders with the opportunity to purchase additional shares at a set price.
• The offering is expected to significantly increase the company's unrestricted cash, potentially by up to $10 million.
• The funds raised are intended to support the company's operations through key regulatory decisions and product launches.
• The inclusion of warrants provides potential for additional upside for investors.
• The offering is structured to prioritize existing shareholders through basic rights and oversubscription privileges.

Negatives

• The subscription rights are non-transferable, limiting flexibility for shareholders.
• Unexercised subscription rights and warrants will expire worthless if the maximum share issuance is reached.
• The offering could lead to dilution for shareholders who do not participate.
• The exercise prices of the warrants are based on a 5-day volume weighted average price, which could be volatile.
• The company cannot guarantee that all oversubscription requests will be fulfilled.

Risks

• The company may not raise the targeted amount of capital through the rights offering.
• The market price of the company's stock could decline, impacting the value of the subscription rights and warrants.
• The company's ability to achieve regulatory approvals and successfully launch new products is not guaranteed.
• The company's financial performance may not improve as expected, despite the increased liquidity.
• The company's debt covenant may not be satisfied, even with the proceeds of the offering.

Future Outlook

The company expects the proceeds from the rights offering to fund operations through anticipated FDA and Health Canada decisions on their DrugSorb-ATR marketing applications in 2025, and if approved or cleared, the initial launch of the product.

Management Comments

• All net proceeds from the offering will go to the Company and be used for general corporate purposes and to satisfy a debt covenant where proceeds of $3.0 million to $5.0 million will unlock $3.0 million to $5.0 million in restricted cash currently on our balance sheet on a dollar-for-dollar basis.
• For example, aggregate proceeds of $5.0 million would result in increased liquidity to the Company of approximately $10.0 million in unrestricted cash, which is expected to fund the Companys operations through anticipated FDA and Health Canada decisions on our DrugSorb-ATR marketing applications in 2025, and if approved or cleared, the initial launch of the product.

Industry Context

This rights offering is a common method for companies to raise capital, particularly in the biotech and medical device sectors, where funding for research, development, and regulatory approvals is crucial. The offering is timed to coincide with the company's anticipated regulatory milestones for its DrugSorb-ATR product.

Comparison to Industry Standards

• The structure of the rights offering, including the use of warrants, is fairly standard in the biotech industry.
• The warrant exercise prices, based on a percentage of the volume weighted average price with a floor and ceiling, are designed to provide some protection against extreme price fluctuations.
• The use of a dealer-manager, Moody Capital Solutions, is typical for offerings of this type.
• The pro-rata allocation of oversubscription privileges is a common practice to ensure fairness to existing shareholders.
• Comparable companies that have recently conducted rights offerings include [list comparable companies if available], which have seen [list comparable results if available].

Stakeholder Impact

• Shareholders have the opportunity to increase their stake in the company at a set price.
• Employees may benefit from the company's improved financial position and potential growth.
• Customers may benefit from the potential launch of new products.
• Creditors may benefit from the company's improved financial stability.
• Suppliers may benefit from increased business with the company.

Next Steps

• Shareholders need to decide whether to exercise their subscription rights before the January 10, 2025 deadline.
• The company will mail subscription rights certificates and a prospectus to eligible shareholders.
• The company will proceed with the regulatory review process for DrugSorb-ATR.
• The company will prepare for the potential launch of DrugSorb-ATR if regulatory approvals are received.

Key Dates

Keywords

rights offering, shareholder rights, warrants, capital raise, liquidity, common stock, subscription rights, oversubscription, DrugSorb-ATR, FDA, Health Canada